Current President and CEO, Samir R. Patel, M.D., to remain as a member of the Company's Board of Directors BOSTON and LONDON, ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for ...

IXIFI is a biosimilar to Remicade (infliximab). It was approved by Health Canada in December 2021 for all eligible indications of the reference product.

A college student from Anthony is speaking out after Blue Cross and Blue Shield of Kansas denied a medicine she has been ...

A college student from Anthony is speaking out. She said Blue Cross and Blue Shield of Kansas have denied a medicine she has ...

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It is more ...

CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian mark ...

The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and ...

The co-developer of Remicade, one of the three top-selling drugs in the world, has donated more than $500,000 to fund what will be known as the Iris and Junming Le Foundation Super-Resolution ...